Cancer
CLARITY GC01
Gastrointestinal Cancer
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2, D9802C00001.
Contact Research Team:
[email protected]
Site principal investigator:
Marc Roth, MD
Learn more about this study:
NCT06346392